Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma

Table 2 Univariate and multivariate Cox regression analysis to identify prognostic factors for survival in stages IIIB and IV lung adenocarcinoma

	HR	95% CI	*P-value*	HR	95% CI	*P-value*
Age	0.996	0.978–1.015	0.711
Gender
Male vs female	0.776	0.483–1.213	0.255
Smoking	0.623	0.384–1.013	0.056
Treatment
Only TKI	1.658	1.028–2.674	0.038	0.972	0.510–1.854	0.932
Only CT	0.234	0.090–0.606	0.003	0.336	0.114–0.990	0.048
TKI + OP	4.601	1.627–13.02	0.004	4.675	1.578–13.85	0.005
TKI + CT	0.462	0.217–0.985	0.045	0.359	0.149–0.867	0.023
TKI + RT	1.518	0.831–2.772	0.175
CT + OP	1.280	0.231–7.099	0.77
CT + RT	0.781	0.408–1.497	0.456
TKI + CT + OP	0.848	0.087–8.250	0.887
Ever TKI	2.295	1.335–3.946	0.003	1.774	0.830–3.791	0.139

P-value < 0.005 is considered as significant difference
Abbreviations: HR Hazard ratio, CI Confidence interval, TKI Tyrosine kinase inhibitor, CT Chemotherapy, OP Operation (lung cancer salvage surgery), RT Radiation therapy

ISSN: 1477-7819